RSS Feed ALL

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

10 days ago

Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of...

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

11 days ago

CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a...

Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference

11 days ago

Johnson & Johnson reinforces its leadership in hematology at ASH 2025 unveiling new paradigm-shifting research

12 days ago

More than 60 abstracts spotlight leading portfolio and pipeline of innovative medicines...

Johnson & Johnson One Year Data Demonstrate Durable Performance and Safety of the Shockwave Javelin Peripheral IVL Catheter in Late-Breaking Presentation at VIVA 2025

12 days ago

Findings demonstrate durable benefits and low complication rates, enabling treatment for severely...

Johnson & Johnson Confirms Durability of IVL in Complex, Below-the-Knee Anatomy in Late-Breaking Presentation at VIVA 2025

14 days ago

DISRUPT BTK II one-year outcomes data demonstrate the strong safety profile and...

Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS

14 days ago

Key oral presentations highlight new safety, efficacy and workflow improvements data to...

Johnson & Johnson submits application to U.S. FDA for STELARA® (ustekinumab) in the treatment of pediatric ulcerative colitis

16 days ago

Expanded STELARA® indication seeks to treat children two years of age and...

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

19 days ago

The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults...

Johnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare

20 days ago

MONARCH ™ Platform for Urology leveraging AI-driven simulation with NVIDIA accelerated compute

Johnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare

21 days ago

First awardees selected for Polyphonic™ AI Fund for Surgery QuickFire Challenge Polyphonic...

New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

21 days ago

Findings highlight opportunity for shared decision-making to improve treatment planning, with more...